New scan could help track rare Cancer's response to treatment
NCT ID NCT06521775
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested whether a special PET/CT scan using a radioactive tracer called Ga-68 PSMA-11 can detect treatment response in patients with metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Six adults with this cancer underwent the scan at two time points. The goal was to see if the imaging could help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ga-68 PSMA-11 (radioactive imaging agent)
- What this could lead to
- If successful, this imaging method could help doctors better track how well treatments are working in patients with this rare cancer.
- What could go wrong
- This is a very small pilot study (6 participants) focused on imaging, not treatment. It may not lead to changes in care or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.